Biomarker and specialty lab data are increasingly being incorporated in FDA submissions given the robust insights they provide on key clinical objectives, including pharmacological effects, and drug safety and effectiveness.
Angela Quigley
Advertisement
Articles by Angela Quigley
Advertisement
Latest Updated Articles
Preparing Specialty Lab Data for FDA Submission in the New Regulatory EnvironmentPublished: March 12th 2018 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
2
Assay Reproducibility in Hemostasis Diagnostics: Practical Methods to Reduce Variability and Strengthen Trial Outcomes
3
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
4
2025 SCRS Global Site Solutions Summit: Best Practices for Building Strong Site Partnerships and Choosing the Right Technology
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
